Physician profile
Daniel H Kwon
NPI 1639736846
$1,303.93
in general payments reported to CMS, 2019-2025
16 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 90% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $125 · 2024: $139 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,303.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $184.30 | 2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $165.65 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.74 | 2025 | Jardiance |
| Neurocrine Biosciences, INC. | $138.50 | 2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2023 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $98.18 | 2025 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $82.56 | 2025 | Gardasil 9, Capvaxive |
| Vivus LLC | $72.20 | 2025 | Pancreaze |
| Sumitomo Pharma America, INC. | $53.01 | 2025 | Gemtesa |
| Astellas Pharma US INC | $50.38 | 2025 | Veozah |
| Lilly USA, LLC | $50.33 | 2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $39.31 | 2025 | |
| Novo Nordisk INC | $34.19 | 2025 | Ozempic, Rybelsus |
| Radius Health, INC. | $21.37 | 2025 | Tymlos |
| Glaxosmithkline, LLC. | $19.34 | 2025 | Trelegy Ellipta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.87 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kwon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.